Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Journal
The New England journal of medicine
Journal Volume
387
Journal Issue
24
Pages
2220
Date Issued
2022-12-15
Author(s)
Dickinson, Michael J
Carlo-Stella, Carmelo
Morschhauser, Franck
Bachy, Emmanuel
Corradini, Paolo
Iacoboni, Gloria
Khan, Cyrus
Wróbel, Tomasz
Offner, Fritz
Trněný, Marek
Cartron, Guillaume
Hertzberg, Mark
Sureda, Anna
Perez-Callejo, David
Lundberg, Linda
Relf, James
Dixon, Mark
Clark, Emma
Humphrey, Kathryn
Hutchings, Martin
Abstract
The prognosis for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is poor. Glofitamab is a bispecific antibody that recruits T cells to tumor cells.
Subjects
Allergy/Immunology | Hematology/Oncology | Leukemia/Lymphoma | T-Cells | Treatments in Oncology
Publisher
Massachussetts Medical Society
Type
journal article